跳至主要内容
临床试验/NL-OMON45357
NL-OMON45357已完成4 期

GLP-1 for bridging of hyperglycaemia during cardiac surgery: a randomized controlled trial - The GLOBE trial

Academisch Medisch Centrum0 个研究点目标入组 274 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
274

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • * Adult patients, aged 18-80 years (inclusive),
  • * No known diabetes mellitus, or
  • * Known diabetes mellitus type 2 on oral glucose lowering medication, diet or total daily insulin dose *0.5 IU/kg
  • * Scheduled for an elective cardiac surgical procedure.
  • * Informed consent obtained before any trial-related activities are carried out.

排除标准

  • * Diabetes mellitus type 1
  • * Emergency surgery
  • * Receiving oral corticosteroid therapy
  • * History of pancreatic surgery or acute or chronic pancreatitis
  • * Personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • * Heart failure NYHA class IV
  • * Serum-creatinine * 133 *mol l-1 for males and * 115 *mol l-1 for females
  • * Female of child-bearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods
  • * Current treatment with GLP-1 analogues
  • * Known or suspected allergy to trial products or other drugs in the same class

研究者

相似试验